^
Association details:
| Biomarker: | AKT1 E17K + BRAF V600 |
|---|---|
| Cancer: | Melanoma |
| Drug: | Tafinlar (dabrafenib) (BRAF inhibitor) + uprosertib (LAE003) (AKT inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma
Excerpt:
Anti-tumor effects of the combination of the BRAF inhibitor (BRAFi) dabrafenib and GSK2141795B (AKTi) in a panel of 23 BRAF mutated melanoma cell lines...melanoma cell lines harboring BRAFV600 mutation...The only known AKT mutant in this series, M262 (AKT1E17K), was also found in the sensitive group (blue bar).
DOI:
10.1186/1476-4598-13-83
